Uterine Transplantation for the Treatment of Uterine Factor Infertility
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02573415|
Recruitment Status : Enrolling by invitation
First Posted : October 9, 2015
Last Update Posted : April 13, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This feasibility study aims to enroll ten subjects who will undergo deceased donor uterine transplantation at Cleveland Clinic. We estimate that fifty to one hundred patients with uterine factor infertility will need to be screened to identify 10 appropriate subjects.
There are seven phases involved in this study: Primary and Secondary Screening, Medical Evaluation, IVF, Transplantation, Embryo Transfer, Pregnancy/Delivery and Follow up
|Condition or disease||Intervention/treatment||Phase|
|Primary Uterine Infertility||Procedure: Uterus Transplant||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Uterine Transplantation for the Treatment of Uterine Factor Infertility|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||October 2025|
|Estimated Study Completion Date :||October 2025|
Experimental: Uterus Transplantation
Women will undergo deceased donor uterine transplantation after IVF.
Procedure: Uterus Transplant
transplant of a deceased donor uterus.
- Number of successful live births after uterus transplant and IVF [ Time Frame: 2 years after transplantation ]Full term birth by cesarian section after IVF followed by uterus transplant
- rate of pregnancy complications after IVF and uterus transplant [ Time Frame: 9 months after successful implantation of embryo ]
The following complications will be monitored:
- intrauterine growth restriction
- premature rupture of membranes
- preterm delivery
- intrauterine fetal demise
- rate of neonatal complications [ Time Frame: birth by cesarian section to discharge from hospital ]
The following neonatal complications will be monitored:
- birth defects
- perinatal infections
- low birth weight
- neonatal death
- neonatal intensive care unit admissions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 45 Years (Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
Must meet criteria for uterine factor infertility
- Prior hysterectomy
- Congenital absence or malformation of the uterus preventing pregnancy c, Infertility due to uterine damage from prior injury or infection
- Must be between the ages of 21-45 and the embryos must have been produced between the age of 21-39. (age at the time the embryos are produced, not current age)
- Must be willing to undergo a psychiatric and social work pre-transplant evaluation
- Must be willing to undergo general anesthesia, in vitro fertilization, major gynecologic surgery, pregnancy with potential high risk complications, cesarean delivery and eventual hysterectomy to remove the graft
- Must be willing and able to receive potent immunosuppressive medications and must be able to follow standard infection prophylaxis protocols
- Must be willing to receive standard vaccinations such as influenza, pneumococcus, human papillomavirus (HPV) and hepatitis B
- Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol
- History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease
- Any medical diagnosis placing the subject at high risk of surgical complications based on the transplant team's review of medical history.
- Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
- History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.
- Human immunodeficiency virus, mycobacteria, hepatitis B (Hepatitis risk is for those with hepatitis B (HB) surface and/or core antigen and/or hepatitis B virus (HBV) DNA positive. Thos that are HB core antibody positive are at minimal risk and everyone else is not at risk), or hepatitis C.
- Presence of active documented systemic infection or recent systemic infection within the past three months
- Chemical and/or alcohol dependency or abuse
- Presence of low lying pelvic kidney(s). Pelvic and horse shoe kidneys are common in the Rokitansky syndrome, and occur with a frequency as high as 30-40%. These abnormalities are usually known to subjects as part of their Mullerian agenesis diagnosis. If the patient is unsure about the status of their kidneys, the performance of a renal ultrasound is considered standard of care. These patients need to be informed of any kidney abnormalities, as they are frequently associated with kidney stones or obstructive kidney disease.
- BMI greater than 30 kg/m2
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02573415
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Koji Hashimoto, MD, PhD||The Cleveland Clinic|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Koji Hashimoto, Staff Physician, The Cleveland Clinic|
|Other Study ID Numbers:||
|First Posted:||October 9, 2015 Key Record Dates|
|Last Update Posted:||April 13, 2023|
|Last Verified:||April 2023|